Open AccessImpact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
Author(s) -
J. Scott Andrews,
David Kudrow,
Mallikarjuna Rettiganti,
Tina M. Oakes,
Jennifer Bardos,
Richard Wenzel,
Dulanji Kuruppu,
Charly Gaul,
J. Michael Martinez
Publication year - 2021
Publication title -
journal of pain research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 49
ISSN - 1178-7090
DOI - 10.2147/jpr.s305066
Subject(s) - placebo , medicine , post hoc analysis , repeated measures design , cluster headache , physical therapy , brief pain inventory , cluster (spacecraft) , chronic pain , statistics , alternative medicine , mathematics , pathology , computer science , programming language , migraine
In a phase 3 study, galcanezumab significantly reduced the frequency of episodic cluster headache attacks across weeks 1-3 (primary endpoint) compared with placebo. However, multiple pain dimensions may contribute to the total burden of episodic cluster headache pain. This post hoc analysis assessed the impact of galcanezumab on the total pain burden of episodic cluster headache using a composite measure.